Bioventus, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Bioventus, Inc.

Butterfly Network, Inc.

908 Devices, Inc.

NeuroPace, Inc.

ZimVie, Inc.

Axogen, Inc.

Standard BioTools, Inc.

Allurion Technologies, Inc.

Celcuity, Inc.

Pulse Biosciences, Inc.

Alpha Tau Medical Ltd.

Why is Bioventus, Inc. ?

Strong Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 7.84%

The company has declared positive results for the last 2 consecutive quarters

OPERATING CASH FLOW(Y) Highest at USD 102.24 MM
NET PROFIT(HY) Higher at USD 20.41 MM
ROCE(HY) Highest at 16.9%

With ROE of 16.65%, it has a very attractive valuation with a 4.04 Price to Book Value

Over the past year, while the stock has generated a return of 35.46%, its profits have risen by 211.6% ; the PEG ratio of the company is 0.1

High Institutional Holdings at 87.33%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 1.35% over the previous quarter.

Consistent Returns over the last 3 years

Along with generating 35.46% returns in the last 1 year, the stock has outperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Bioventus, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Bioventus, Inc. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Bioventus, Inc.

35.46%

0.67

51.52%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

12.08%

EBIT Growth (5y)

11.68%

EBIT to Interest (avg)

2.27

Debt to EBITDA (avg)

4.88

Net Debt to Equity (avg)

2.20

Sales to Capital Employed (avg)

1.05

Tax Ratio

13.26%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

87.33%

ROCE (avg)

7.84%

ROE (avg)

6.25%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.04

EV to EBIT

17.25

EV to EBITDA

9.48

EV to Capital Employed

2.30

EV to Sales

1.74

PEG Ratio

0.12

Dividend Yield

ROCE (Latest)

13.32%

ROE (Latest)

16.65%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

20What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 102.24 MM

NET PROFIT(HY)

Higher at USD 20.41 MM

ROCE(HY)

Highest at 16.9%

RAW MATERIAL COST(Y)

Fallen by -3.27% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at 133.71 %

INVENTORY TURNOVER RATIO(HY)

Highest at 2.1 times

DEBTORS TURNOVER RATIO(HY)

Highest at 4.83 times

-5What is not working for the Company

NET PROFIT(Q)

At USD 3.53 MM has Fallen at -46%

PRE-TAX PROFIT(Q)

At USD 4.99 MM has Fallen at -31.85%

Here's what is working for Bioventus, Inc.

Operating Cash Flow

Highest at USD 102.24 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debt-Equity Ratio

Lowest at 133.71 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Inventory Turnover Ratio

Highest at 2.1 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 4.83 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -3.27% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Bioventus, Inc.

Net Profit

At USD 3.53 MM has Fallen at -46%

over average net sales of the previous four periods of USD 6.53 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Pre-Tax Profit

At USD 4.99 MM has Fallen at -31.85%

over average net sales of the previous four periods of USD 7.32 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)